Now, the company claims the trial results support a monthly or twice-monthly dosing regimen of the selective small molecule agonist. The trial was run in two parts, the first was a single ...

For the antigen-attached molecule, the authors selected an activator (agonist) of the STING protein. STING is found on the surface of the ER and can trigger inflammatory responses similar to those ...

an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism. The company decided to discontinue the trial following two unanticipated severe ...

Scientists realised the molecule latched onto the same receptors as GLP-1 but didn't break down as quickly. It could decrease blood sugar levels in mice and people with type 2 diabetes for hours.